Aminopyrimidine/Pyrazine Derivatives as CTPS1 Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,371,419 | Aminopyrimidine/Pyrazine Derivatives as CTPS1 Inhibitors In force · High confidence | Step Pharma S.A.S | In force | High confidence | ||
| US 11,987,573 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors In force · High confidence | Sygnature Discovery Limited | In force | High confidence | ||
| Application 19/217,739 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors Pending Not granted | Step Pharma S.A.S. | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Step Pharma S.A.S..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.